Sarat Ventures has launched a specialized biotechnology investment fund that aims to deploy USD 100 million across 15 to 20 companies. The Saudi-based investment and innovation vehicle will focus on later-stage businesses with commercial operations and annual revenues of up to approximately USD 2 million. The initiative marks a new effort to strengthen Saudi Arabia's biotechnology sector through targeted venture capital.
Strategy Focuses on Commercially Active Companies
The fund targets companies that have reached Series A financing or beyond and have started commercial, manufacturing, and sales activities. Founder Dr. Huda Al Fardous said this approach creates more opportunities for investment exits while reducing exposure to the higher risks of early-stage ventures. The strategy also reflects a preference for companies that have already demonstrated revenue generation and operational momentum.
Supporting Local Founders and Attracting International Companies
Beyond capital, Sarat Ventures aims to help international companies establish operations in Saudi Arabia and support local founders in developing and exporting their products. Its team has previous experience building a specialized biotechnology accelerator, which provides familiarity with the local market and entrepreneurs. This dual approach is intended to strengthen the Kingdom's biotechnology value chain and expand access to overseas markets.
Fund Registration and Global Partnerships
Sarat Ventures was established in Saudi Arabia and has partnerships with entities in the United States and China. The fund is registered in London, a structure that Al Fardous said has allowed it to broaden investment activity within and outside the Kingdom and attract foreign investment. These partnerships are expected to support international collaboration and give portfolio companies access to a wider network.
A Five-Year Investment and Reinvestment Model
The fund is structured around a five-year investment period, after which it plans to exit its holdings. It then intends to reinvest through a second five-year cycle with a target size approximately five times larger than the current vehicle. This model aligns with its venture investment mandate and signals a long-term commitment to the biotechnology sector.
Saudi Biotechnology Market Expected to Reach USD 150 Billion
Al Fardous expects Saudi Arabia's biotechnology market to reach approximately USD 150 billion by 2030, with annual growth of around 13.5 percent. Continued expansion at that rate would benefit venture investors, local founders, and international companies seeking a presence in the Kingdom. Sarat Ventures is among the early specialized biotechnology investment funds in Saudi Arabia, which positions it close to emerging market opportunities.
What to Watch
The next signal will be the type of companies Sarat Ventures backs and how quickly it deploys the targeted USD 100 million. The profile of these investments will indicate where the fund sees the strongest commercial traction in Saudi Arabia's biotechnology market. Its five-year exit and reinvestment cycle will also serve as a longer-term measure of whether the model can support a larger second fund.
Sarat Ventures' USD 100 million fund represents a notable step in Saudi Arabia's evolving biotechnology investment landscape. Its focus on companies with existing commercial traction and revenue may provide a clearer path to exits while still supporting the growth of the local ecosystem. The planned reinvestment cycle and international partnerships indicate that the fund intends to play a long-term role in connecting Saudi Arabia with global biotechnology opportunities.